Highlights

  • FY26 Revenue was US$15.797 billion, while restructuring and Impairment charges drove a statutory net loss of US$2.579 billion.
  • Underlying NPATA was US$3.098 billion, with CSL Behring remaining the largest contributor to group revenue.
  • CSL is targeting US$400 million of annual pre-tax savings in FY27 as it continues a wider cost reset.
  • FY27 guidance points to mid single-digit constant-currency revenue growth at Behring and continued pressure at CSL Vifor.
  • Leverage was reported at 1.8 times net Debt to EBITDA, within the company's stated target range.

CSL Limited (ASX:CSL) is a global biotechnology company operating across plasma-derived therapies, influenza vaccines and specialty medicines through CSL Behring, CSL Seqirus and CSL Vifor. Its FY26 result showed a clear split between operating performance and large accounting write-downs, making the outlook for Behring, cost reduction and Vifor central to the next phase of the business.

FY26 Earnings Reflect Major Impairments

For FY26, CSL reported revenue of US$15.797 billion and a statutory net loss of US$2.579 billion. Restructuring and impairment charges totalled US$5.416 billion after tax, while underlying NPATA was US$3.098 billion. The gap shows that the headline loss was driven mainly by write-downs rather than the core operating result.

The largest impairment exposure sat in CSL Vifor, reflecting lower growth assumptions, generic competition in intravenous iron and changes in the US dialysis market. Other charges related to additional Assets and Manufacturing investments. Although non-cash, the write-downs indicate that earlier asset values and growth assumptions have been revised.

Behring Remains the Main Operating Engine

CSL Behring generated US$11.387 billion of FY26 revenue at a 40.5% operating margin, remaining the group's largest contributor. CSL Seqirus recorded US$2.031 billion of revenue and CSL Vifor US$2.379 billion. CSL is also investing US$1.5 billion in expanded plasma manufacturing capacity at Kankakee in Illinois.

For FY27, management expects mid single-digit constant-currency revenue growth at Behring, with immunoglobulin growth in the mid to high single digits. Seqirus is expected to grow at a low single-digit rate, while Vifor remains under pressure from generics and reimbursement changes.

Cost Reset Becomes Central to FY27

The FY27 outlook relies heavily on efficiency measures. CSL delivered US$176 million of annual pre-tax savings in FY26 and is targeting US$400 million in FY27 and US$550 million by FY28. Around half of incremental savings are intended to be reinvested in growth, making cost execution and pipeline Investment a key balance.

CSL expects Underlying Profit growth of about 5% in FY27 despite broadly flat group revenue. With Vifor revenue expected to decline materially, earnings growth depends more on Behring and internal efficiency. CSL has also indicated that roughly US$200 million of further impairments may be recorded in FY27.

Capital Position and Key Risks

CSL reported Operating Cash Flow of US$3.512 billion and Leverage of 1.8 times net debt to EBITDA, within its 1.5 to 2.0 times target range. The FY26 total Dividend was US$2.92 per share, including a US$1.62 final dividend. CSL also completed a A$1 billion buy-back and announced another of about A$1.1 billion.

Key risks include Vifor's decline, plasma supply, product quality, manufacturing execution, reimbursement changes, Vaccine Demand and delivery of savings without weakening future investment. Leadership continuity is also a watch point following Gordon Naylor's appointment as interim chief executive in 2026.

Key Insights

CSL's FY26 result combined a large impairment-driven statutory loss with continued underlying profitability. FY27 now centres on execution: Behring needs to maintain immunoglobulin growth, the cost programme needs to deliver savings, and Vifor's decline needs to be managed. Cash generation and leverage remain important support factors during the reset.